Caris Life Sciences, Inc. (NASDAQ:CAI)
| Market Cap | 8.47B-10.3% |
| Revenue (ttm) | 989.61M+85.4% |
| Net Income | 105.14M+137.7% |
| EPS | 0.36+112.7% |
| Shares Out | 282.68M |
| PE Ratio | 80.61 |
| Forward PE | 84.67 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,722,330 |
| Open | 30.36 |
| Previous Close | 30.92 |
| Day's Range | 29.69 - 30.99 |
| 52-Week Range | 14.19 - 34.12 |
| Beta | 0.68 |
| Analysts | Buy |
| Price Target | 26.00(-13.28%) |
| Earnings Date | Nov 4, 2026 |
Caris Life Sciences, Inc. has a live Insider Score.
Scored on 0 qualifying trades from 0 insiders in the last 90 days.
About CAI
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$CAI stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in CAI holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CAI's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CAI Estimated quarterly lobbying spending
Source: U.S. Senate LDA
CAI Revenue by Segment or Geography
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New CAI patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CAI from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CAI
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $103.43M |
| VBVanguard Morningstar Small-Cap ETF | $74.57M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $42.93M |
| IBBiShares Biotechnology ETF | $26.53M |
| IWPiShares Russell Mid-Cap Growth ETF | $17.59M |
| IWRiShares Russell Mid-Cap ETF | $14.30M |
Estimated from each fund’s disclosed top holdings × AUM
CAI Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CAI’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score